Quantcast
Last updated on April 20, 2014 at 14:04 EDT

BRIC Gastric Cancer Market Forecast until 2020 in New GlobalData Study Available at MarketPublishers.com

September 5, 2012

New research study “Gastric Cancer – Brazil, Russia, India and China (BRIC) Drug Forecasts and Treatment Analysis to 2020” prepared by GlobalData has been recently published by Market Publishers Ltd. The report finds that the global gastric cancer drug market will experience robust growth over the next decade.

London, UK (PRWEB) September 04, 2012

The global gastric cancer drug market will experience robust growth over the next decade, driven by the rapid uptake and market expansion of Roche/Genentech/Chugai´s Herceptin as well as the launches and uptake of two premium-priced targeted agents.

New research study “Gastric Cancer – Brazil, Russia, India and China (BRIC) Drug Forecasts and Treatment Analysis to 2020” prepared by GlobalData has been recently published by Market Publishers Ltd.

Report Details:

Title: Gastric Cancer – Brazil, Russia, India and China (BRIC) Drug Forecasts and Treatment Analysis to 2020

Published: April, 2011

Pages: 187

Price: US$ 3,500.00

http://marketpublishers.com/report/medicine_pharmaceuticals_biotechnology/healthcare_equipment_services/gastric-cancer-brazil-russia-india-n-china-bric-drug-forecasts-n-treatment-analysis-to-2020.html

The report offers a comprehensive guide to the gastric cancer therapeutics market in the emerging BRIC countries – Brazil, Russia, India and China. The study identifies and analyzes the key trends shaping and driving the market; analyzes the treatment usage patterns; presents an overview of the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders; provides valuable insights into the pipeline products within the global gastric cancer sector; as well as quantifies the unmet need in the BRIC gastric cancer therapeutics market, highlighting the opportunity for future players.

Key current and future market players mentioned include: Novartis AG, GlaxoSmithKline, Hoffmann-La Roche Ltd., Eli Lilly and Company, Otsuka Holdings Co., Ltd./Otsuka Pharmaceutical Co., Ltd., and Merck KGaA.

Report Contents:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Disease Overview

2.1.1 TNM (Tumor, Nodes, Metastasis) Staging System

2.2 Epidemiology

2.3 Etiology

2.4 Symptoms

2.4.1 Initial Symptoms

2.4.2 Symptoms Observed in Later Stages

2.5 Diagnosis

2.5.1 Fecal Occult Blood Test (FOBT)

2.5.2 X-ray of Upper Gastrointestinal Tract (GI Series)

2.5.3 Endoscopy (Gastroscopy)

2.5.4 Computed Tomography (CT)

2.5.5 Biopsy

2.6 Pathology

2.6.1 Grading

2.7 Prognosis

2.8 Treatment

2.8.1 Gastric Cancer Treatment Options

2.9 Treatment Guidelines

2.10 GlobalData Report Guidance

3 Market Characterization

3.1 Brazil, Russia, India and China

3.1.1 Market Size

3.1.2 Forecasts

3.2 Brazil

3.2.1 Market Size

3.2.2 Drivers and Restraints

3.2.3 Impact on the Market

3.2.4 Forecasts

3.2.5 Future Impact

3.3 Russia

3.3.1 Market Size

3.3.2 Drivers and Restraints

3.3.3 Impact on the Market

3.3.4 Forecasts

3.3.5 Future Impact

3.4 India

3.4.1 Market Size (2002-2010)

3.4.2 Drivers and Restraints

3.4.3 Impact on the Market

3.4.4 Forecasts (2010-2020)

3.4.5 Future Impact

3.5 China

3.5.1 Market Size (2002-2010)

3.5.2 Drivers and Restraints

3.5.3 Impact on the Market

3.5.4 Forecasts (2010-2020)

3.5.5 Future Impact

3.6 Key Takeaway

4 Gastric Cancer Market: Competitive Assessment

4.1 Strategic Competitor Assessment

4.1.1 Overview

4.1.2 Benchmarking

4.1.3 Current Competitor Assessment

4.2 Product Profiles of Major Marketed Drugs in the Gastric Cancer Market

4.2.1 Herceptin (trastuzumab)

4.2.2 Taxotere (docetaxel)

4.2.3 Teysuno

4.2.4 Xeloda

4.3 Key Takeaway

5 Gastric Cancer Market: Pipeline Assessment

5.1 Overview

5.2 Pipeline Analysis by Phase of Development

5.3 Pipeline by Mechanism of Action

5.4 Strategic Pipeline Assessment

5.4.1 Technology Trends Analytic Framework

5.5 Gastric Cancer — Promising Drugs Under Clinical Development

5.6 Partners in Development

5.6.1 Licensing Agreements

5.6.2 Research and Development Partnership Agreements

5.6.3 Technology and Diagnostic Agreements

5.7 Molecule Profile for Promising Drugs Under Clinical Development

5.7.1 Tykerb (Lapatinib)

5.7.2 Afinitor (Everolimus)

5.7.3 IMC-1121B (ramucirumab)

5.7.4 Cetuximab plus capecitabine and cisplatin

5.7.5 Apatinib (YN968DI)

5.8 Key Takeaway

6 Clinical Trials Mapping

6.1 Clinical Trials

6.1.1 Clinical Trials by Status

6.1.2 Clinical Trials by Country

6.1.3 Clinical Trials by Phase

6.1.4 Clinical Trials by Sponsor Type

6.1.5 Clinical Trials — Leading Sponsors

6.1.6 Clinical Trials — Leading Company Sponsors by Phase

More new market research reports by the publisher can be found at GlobalData page.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/9/prweb9866078.htm


Source: prweb